Ortho Clinical Diagnostics Holdings plc (Ortho), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, has announced the pricing of its initial public offering of 76 million ordinary shares at US$17 per share. The gross proceeds raised from this offering are expected to be US$1,292 million. Ortho's ordinary shares are expected to begin trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX," and the offering is expected to close on February 1, 2021, subject to customary closing conditions. Latham & Watkins LLP represents Ortho in the offering with a cross-border capital markets deal team led by Washington, D.C. partners Patrick Shannon and Jason Licht and Washington, D.C. counsel Christopher Cronin, with London partners Richard Butterwick, Sean Finn, and Anna Ngo, Washington, D.C. associates Jess Lennon, Lucas Balchun, Gabrielle Blum, and CJ Harrington, and London associates Drishi Beeharry and Koushik Prasad.~~